Riverbridge Partners Reduces Repligen Corporation Stake

Institutional investor sells 30,070 shares of biotech company's stock

Mar. 27, 2026 at 10:40am

Got story updates? Submit your updates here. ›

Riverbridge Partners LLC, an institutional investor, reduced its position in Repligen Corporation (NASDAQ:RGEN) by 8.8% during the fourth quarter, according to a recent 13F filing. The firm now owns approximately 313,365 shares of the biotechnology company's stock, valued at around $51.3 million.

Why it matters

This transaction provides insight into the investment strategy and portfolio adjustments of a major institutional investor. Repligen is a prominent biotech firm focused on developing and manufacturing high-value consumable products for bioprocessing applications, so changes to major stakeholder positions can be noteworthy.

The details

Riverbridge Partners sold 30,070 shares of Repligen stock during the fourth quarter, reducing its overall stake in the company by 8.8%. After the sale, Riverbridge Partners now owns approximately 313,365 shares of Repligen, valued at around $51.3 million and representing about 0.56% of the company's outstanding shares.

  • Riverbridge Partners reduced its Repligen position during the fourth quarter of 2025.

The players

Riverbridge Partners LLC

An institutional investment firm that previously held a sizable stake in Repligen Corporation.

Repligen Corporation

A life sciences company that develops and manufactures high-value consumable products for bioprocessing applications.

Got photos? Submit your photos here. ›

The takeaway

This transaction reflects Riverbridge Partners' portfolio adjustments, potentially in response to market conditions or investment strategy changes. As a major shareholder, the firm's moves can provide insights into the perceived outlook for Repligen's business and the broader biotech industry.